Literature DB >> 26390826

Recurrent neonatal herpes simplex virus infection with central nervous system disease after completion of a 6-month course of suppressive therapy: Case report.

Koji Kato1, Shinya Hara1, Jun-Ichi Kawada2, Yoshinori Ito3.   

Abstract

A boy at 12 days of age developed neonatal herpes simplex virus (HSV) type 2 infection with central nervous system (CNS) disease. After a 21-day course of high-dose intravenous acyclovir, the patient recovered with negative results for HSV DNA in serum and cerebrospinal fluid. Two weeks after a 6-month course of oral valacyclovir suppressive therapy with negative virological assessment, the disease recurred. Another 21-day course of intravenous acyclovir and subsequent 1-year course of oral suppressive therapy were completed. He showed mild developmental delay in language-social skills at 18 months of age. Although recurrences of neonatal HSV infection with CNS disease after suppressive therapy are uncommon, both clinical and virological assessments at the end of the suppressive therapy may be required. Administration of extended long-term suppressive ACV therapy should be considered to reduce the rate of recurrence.
Copyright © 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CNS disease; Neonatal HSV infection; Recurrence; Suppressive therapy

Mesh:

Substances:

Year:  2015        PMID: 26390826     DOI: 10.1016/j.jiac.2015.08.005

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  3 in total

Review 1.  Neonatal Herpes Simplex Viral Infections and Acyclovir: An Update.

Authors:  John Brock Harris; Amy P Holmes
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Mar-Apr

2.  Neonatal Herpes Simplex Virus Infection: Epidemiology and Outcomes in the Modern Era.

Authors:  Ann J Melvin; Kathleen M Mohan; Surabhi B Vora; Stacy Selke; Erin Sullivan; Anna Wald
Journal:  J Pediatric Infect Dis Soc       Date:  2022-03-24       Impact factor: 5.235

Review 3.  Viral meningitis: an overview.

Authors:  Amira Kohil; Sara Jemmieh; Maria K Smatti; Hadi M Yassine
Journal:  Arch Virol       Date:  2021-01-03       Impact factor: 2.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.